Lung Carcinoma Antibody (MOC-31): sc-52344

Lung Carcinoma Antibody (MOC-31) is a mouse monoclonal IgG1 antibody that detects Lung Carcinoma by western blotting (WB), immunofluorescence (IF), and immunohistochemistry. Lung Carcinoma monoclonal antibody (MOC-31) is available in a non-conjugated form, providing researchers with a versatile tool for studying this aggressive cancer type. Lung carcinoma, characterized by uncontrolled growth of lung tissue, is the leading cause of cancer-related deaths worldwide, claiming approximately 3 million lives each year. Lung Carcinoma (MOC-31) antibody targets a protein that plays a critical role in tumor progression and metastasis, making this protein a vital target for therapeutic intervention. Notably, lung carcinoma can be classified into two primary subtypes: non-small cell lung carcinoma, which accounts for about 80% of cases, and small-cell lung carcinoma, representing roughly 20%. Specific proteins that interact with Lung Carcinoma can influence the disease′s aggressiveness and response to treatment, highlighting the importance of understanding these interactions for developing targeted therapies. As the incidence of lung cancer continues to rise, particularly among women, ongoing research into the molecular mechanisms underlying this disease is essential for improving patient outcomes and developing more effective treatment strategies.